Danaher
Market Cap
US$112.7b
Last Updated
2020/02/23 00:13 UTC
Data Sources
Company Financials +
Executive Summary
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Moderate growth potential with questionable track record.
Similar Companies
Share Price & News
How has Danaher's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DHR has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.5%
DHR
-1.3%
US Medical Equipment
-1.1%
US Market
1 Year Return
42.7%
DHR
19.6%
US Medical Equipment
17.9%
US Market
Return vs Industry: DHR exceeded the US Medical Equipment industry which returned 19.6% over the past year.
Return vs Market: DHR exceeded the US Market which returned 17.9% over the past year.
Shareholder returns
| DHR | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.5% | -1.3% | -1.1% |
| 30 Day | -0.2% | -0.03% | 1.4% |
| 90 Day | 11.7% | 5.8% | 6.9% |
| 1 Year | 43.3%42.7% | 20.6%19.6% | 20.3%17.9% |
| 3 Year | 91.4%88.1% | 79.2%74.2% | 47.8%38.3% |
| 5 Year | 152.0%85.5% | 115.2%92.6% | 71.9%53.0% |
Price Volatility Vs. Market
How volatile is Danaher's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Estimating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)2 months ago | Simply Wall St
How Much Are Danaher Corporation (NYSE:DHR) Insiders Taking Off The Table?2 months ago | Simply Wall St
Is Danaher Corporation's (NYSE:DHR) P/E Ratio Really That Good?Valuation
Is Danaher undervalued compared to its fair value and its price relative to the market?
48.96x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DHR ($161.88) is trading above our estimate of fair value ($134.31)
Significantly Below Fair Value: DHR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DHR is poor value based on its PE Ratio (49x) compared to the Medical Equipment industry average (46.6x).
PE vs Market: DHR is poor value based on its PE Ratio (49x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: DHR is poor value based on its PEG Ratio (3.1x)
Price to Book Ratio
PB vs Industry: DHR is good value based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Danaher forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
15.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DHR's forecast earnings growth (15.6% per year) is above the savings rate (1.7%).
Earnings vs Market: DHR's earnings (15.6% per year) are forecast to grow faster than the US market (14.1% per year).
High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.
Revenue vs Market: DHR's revenue (8.7% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: DHR's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (15.4%).
Next Steps
Past Performance
How has Danaher performed over the past 5 years?
6.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DHR has high quality earnings.
Growing Profit Margin: DHR's current net profit margins (13.2%) are lower than last year (13.3%).
Past Earnings Growth Analysis
Earnings Trend: DHR's earnings have grown by 6.6% per year over the past 5 years.
Accelerating Growth: DHR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DHR had negative earnings growth (-10.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.7%).
Return on Equity
High ROE: DHR's Return on Equity (8%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Danaher's financial position?
Financial Position Analysis
Short Term Liabilities: DHR's short term assets ($25.6B) exceed its short term liabilities ($4.9B).
Long Term Liabilities: DHR's short term assets ($25.6B) do not cover its long term liabilities ($26.9B).
Debt to Equity History and Analysis
Debt Level: DHR's debt to equity ratio (68.5%) is considered high.
Reducing Debt: DHR's debt to equity ratio has increased from 14.8% to 68.5% over the past 5 years.
Debt Coverage: DHR's debt is not well covered by operating cash flow (19.1%).
Interest Coverage: DHR earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: DHR has a low level of unsold assets or inventory.
Debt Coverage by Assets: DHR's debt is covered by short term assets (assets are 1.2x debt).
Next Steps
Dividend
What is Danaher's current dividend yield, its reliability and sustainability?
0.44%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: DHR's dividend (0.44%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: DHR's dividend (0.44%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stability and Growth of Payments
Stable Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DHR is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Tom Joyce (58yo)
5.4yrs
Tenure
US$15,361,041
Compensation
Mr. Thomas P. Joyce, Jr., also known as Tom, has been the Chief Executive Officer and President of Danaher Corp. since September 9, 2014. Mr. Joyce serves as a Director of MedStar Health, Inc. Mr. Joyce se ...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD15.36M) is above average for companies of similar size in the US market ($USD10.81M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.4yrs | US$15.36m | 0.023% $26.3m | |
| Executive Vice President | 1.1yrs | US$6.85m | 0.022% $25.2m | |
| Executive Vice President | 11.6yrs | US$6.17m | 0.013% $14.4m | |
| Executive Vice President | 3.1yrs | US$5.09m | 0.0039% $4.4m | |
| Executive Vice President | 2.3yrs | US$4.44m | 0.0094% $10.6m | |
| Co-Founder & Chairman | 36.1yrs | no data | 6.19% $7.0b | |
| Co-Founder & Director | 37.1yrs | no data | 5.08% $5.7b | |
| CFO & Executive VP | 1.1yrs | no data | 0.0043% $4.9m | |
| Chief Accounting Officer & Senior VP | 10yrs | no data | 0.0028% $3.2m | |
| Vice President of Investor Relations | 0yrs | no data | no data |
3.1yrs
Average Tenure
55yo
Average Age
Experienced Management: DHR's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.4yrs | US$15.36m | 0.023% $26.3m | |
| Co-Founder & Chairman | 36.1yrs | no data | 6.19% $7.0b | |
| Co-Founder & Director | 37.1yrs | no data | 5.08% $5.7b | |
| Independent Director | 21.1yrs | US$279.82k | 0.0088% $9.9m | |
| Lead Independent Director | 0yrs | US$329.82k | 0.023% $25.6m | |
| Independent Director | 37.1yrs | US$279.82k | 0.070% $78.6m | |
| Independent Director | 16.6yrs | US$304.82k | 0.0027% $3.1m | |
| Independent Director | 11.1yrs | US$279.82k | 0.0011% $1.2m | |
| Independent Director | 14.2yrs | US$294.82k | 0.0030% $3.4m | |
| Independent Director | 8.4yrs | US$279.82k | no data |
16.6yrs
Average Tenure
68yo
Average Age
Experienced Board: DHR's board of directors are seasoned and experienced ( 16.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DHR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Top Shareholders
Company Information
Danaher Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Danaher Corporation
- Ticker: DHR
- Exchange: NYSE
- Founded: 1969
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$112.707b
- Shares outstanding: 696.24m
- Website: https://www.danaher.com
Number of Employees
Location
- Danaher Corporation
- 2200 Pennsylvania Avenue NW
- Suite 800W
- Washington
- District Of Columbia
- 20037
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DHR | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Nov 1969 |
| DAP | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 1969 |
| DAP | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Nov 1969 |
| DHR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Nov 1969 |
| DHR | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Nov 1969 |
| 0R2B | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Nov 1969 |
| DAP | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Nov 1969 |
| DHRC | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Nov 1969 |
| DHER34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR REPR 1/4 COM SHS USD0.01 | BR | BRL | Jul 2015 | |
| DHR.PRA | NYSE (New York Stock Exchange) | 4.75 MND CV PFD | US | USD | Feb 2019 |
Biography
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company’s Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The company’s Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides analytical instruments, software, services, and consumables for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/23 00:13 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.